Efficacy of common antiseptic solutions against clinically relevant microorganisms in biofilm

dc.contributor.authorO’Donnell, Jeffrey A.
dc.contributor.authorWu, Mark
dc.contributor.authorCochrane, Niall H.
dc.contributor.authorBelay, Elshaday
dc.contributor.authorMyntti, Matthew F.
dc.contributor.authorJames, Garth A.
dc.contributor.authorRyan, Sean P.
dc.contributor.authorSeyler, Thorsten M.
dc.date.accessioned2022-05-18T21:30:46Z
dc.date.available2022-05-18T21:30:46Z
dc.date.issued2021-05
dc.description.abstractAims Periprosthetic joint infections (PJIs) are among the most devastating complications after joint arthroplasty. There is limited evidence on the efficacy of different antiseptic solutions on reducing biofilm burden. The purpose of the present study was to test the efficacy of different antiseptic solutions against clinically relevant microorganisms in biofilm. Methods We conducted an in vitro study examining the efficacy of several antiseptic solutions against clinically relevant microorganisms. We tested antiseptic irrigants against nascent (four-hour) and mature (three-day) single-species biofilm created in vitro using a drip-flow reactor model. Results With regard to irrigant efficacy against biofilms, Povidone-iodine treatment resulted in greater reductions in nascent MRSA biofilms (logarithmic reduction (LR) = 3.12; p < 0.001) compared to other solutions. Bactisure treatment had the greatest reduction of mature Pseudomonas aeruginosa biofilms (LR = 1.94; p = 0.032) and a larger reduction than Vashe or Irrisept for mature Staphylococcus epidermidis biofilms (LR = 2.12; p = 0.025). Pooled data for all biofilms tested resulted in Bactisure and Povidone-iodine with significantly greater reductions compared to Vashe, Prontosan, and Irrisept solutions (p < 0.001). Conclusion Treatment failure in PJI is often due to failure to clear the biofilm; antiseptics are often used as an adjunct to biofilm clearance. We tested irrigants against clinically relevant microorganisms in biofilm in vitro and showed significant differences in efficacy among the different solutions. Further clinical outcome data is necessary to determine whether these solutions can impact PJI outcome in vivo.en_US
dc.identifier.citationO’Donnell, J. A., Wu, M., Cochrane, N. H., Belay, E., Myntti, M. F., James, G. A., ... & Seyler, T. M. (2021). Efficacy of common antiseptic solutions against clinically relevant microorganisms in biofilm. The bone & joint journal, 103(5), 908-915.en_US
dc.identifier.issn2049-4394
dc.identifier.urihttps://scholarworks.montana.edu/handle/1/16795
dc.language.isoen_USen_US
dc.publisherBritish Editorial Society of Bone & Joint Surgeryen_US
dc.titleEfficacy of common antiseptic solutions against clinically relevant microorganisms in biofilmen_US
dc.typeArticleen_US
mus.citation.extentfirstpage908en_US
mus.citation.extentlastpage915en_US
mus.citation.issue5en_US
mus.citation.journaltitleThe Bone & Joint Journalen_US
mus.citation.volume103-Ben_US
mus.data.thumbpage1en_US
mus.identifier.doi10.1302/0301-620x.103b5.bjj-2020-1245.r2en_US
mus.relation.collegeCollege of Engineeringen_US
mus.relation.departmentCenter for Biofilm Engineering.en_US
mus.relation.researchgroupCenter for Biofilm Engineering.en_US
mus.relation.universityMontana State University - Bozemanen_US

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ODonnell-efficacy-2021.pdf
Size:
710.52 KB
Format:
Adobe Portable Document Format
Description:
Efficacy of common antiseptic solutions against clinically relevant microorganisms in biofilm

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
826 B
Format:
Item-specific license agreed upon to submission
Description:
Copyright (c) 2002-2022, LYRASIS. All rights reserved.